دورية أكاديمية
Once-a-week versus once-every-3-weeks cisplatin in patients receiving chemoradiation for locally advanced head-and-neck cancer: A survey of practice in India
| العنوان: | Once-a-week versus once-every-3-weeks cisplatin in patients receiving chemoradiation for locally advanced head-and-neck cancer: A survey of practice in India |
|---|---|
| المؤلفون: | Gautam Goyal, Vijay M Patil, Vanita Noronha, Amit Joshi, Satvik Khaddar, Sajak Kakkar, Ritesh Pruthy, Purvish Parikh, Kumar Prabhash |
| المصدر: | Cancer Research, Statistics, and Treatment, Vol 1, Iss 1, Pp 63-67 (2018) |
| بيانات النشر: | Wolters Kluwer Medknow Publications, 2018. |
| سنة النشر: | 2018 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | chemoradiation, cisplatin, concurrent chemoradiation, concurrent chemotherapy, head-and-neck cancer, once-a-week, once-every-3-weeks, radiotherapy, survey, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Purpose: High-dose (100 mg/m2) cisplatin with radiotherapy is the standard practice in locally advanced head-and-neck squamous cell carcinoma. Use of this regimen in resource- constrained and economically constrained countries like India is difficult. Methods: This study was a cross-sectional survey conducted among Indian oncologists treating head-and-neck cancer. The survey consisted of 25 questions relevant to general day-to-day practice in head-and-neck oncology. It included questions regarding the most common drug used in the concurrent chemoradiation (CRT) setting, the most common schedule of administration of cisplatin, the doses used in once-a-week or once-every-3-week cisplatin chemoradiotherapy, toxicities, and preventive strategies. Descriptive analysis was performed using SPSS software version 20. Results: Responses were obtained from 257 oncologists practicing in various oncology centers throughout the country. The agent most commonly used for radiosensitization was cisplatin (n = 243; 94.6%). The once-a-week regimen of cisplatin was the favored regimen (87.9%, n = 226). The reason for favoring the once-a-week regimen was better tolerance (n = 153, 59.5%). The once-every-3-weeks cisplatin schedule was prescribed for >50% of head-and-neck cancer patients by 23 participants only (8.9%). Conclusion: In this nationwide Indian survey, the majority of clinicians preferred the once-a-week cisplatin schedule for CRT in locally advanced head-and-neck cancer patients, due to better tolerance. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2590-3233 2590-3225 |
| Relation: | http://www.crstonline.com/article.asp?issn=2590-3233;year=2018;volume=1;issue=1;spage=63;epage=67;aulast=; https://doaj.org/toc/2590-3233; https://doaj.org/toc/2590-3225 |
| DOI: | 10.4103/CRST.CRST_15_18 |
| URL الوصول: | https://doaj.org/article/8b8e83200b3e4138960a80f4ec595262 |
| رقم الأكسشن: | edsdoj.8b8e83200b3e4138960a80f4ec595262 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 25903233 25903225 |
|---|---|
| DOI: | 10.4103/CRST.CRST_15_18 |